LifeVantage Corporation (LFVN)

Market Cap	44.13M
Revenue (ttm)	206.38M
Net Income (ttm)	-723,000
Shares Out	12.72M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	$0.12 (3.45%)
Ex-Dividend Date	Feb 28, 2023

Volume	10,068
Open	3.45
Previous Close	3.45
Day's Range	3.45 - 3.68
52-Week Range	3.24 - 5.24
Beta	1.12
Analysts	Buy
Price Target	7.14 (+105.17%)
Earnings Date	May 2, 2023

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to suppo...

• Industry: Packaged Foods
• Sector: Consumer Staples
• CEO: Mr. Steven R. Fife
• Employees: 259
• Stock Exchange: NASDAQ
• Ticker Symbol: LFVN

Financial Performance

In 2022, LifeVantage's revenue was $206.36 million, a decrease of -6.28% compared to the previous year's $220.18 million. Earnings were $3.12 million, a decrease of -75.80%.

Analyst Forecast

According to 7 analysts, the average rating for LFVN stock is "Buy." The 12-month stock price forecast is $7.14, which is an increase of 105.17% from the latest price.

Price Target

$7.14

(105.17% upside)

Analyst Consensus: Buy